
Woman claims she contracted genital herpes virus from a nail salon... the dire mistake she made
The anonymous woman said she visited PDX Nails near Portland, Oregon, for an acrylic nail manicure on June 1, 2023.
However, what was meant to be simple beauty service, typically priced between $58 to $70, allegedly resulted in the contraction of the STI herpes virus.
Hours later, the woman noticed swelling on her right index finger and began to feel ill.
Four days later, she developed painful blisters on her fingers and visited a local urgent care clinic.
Seeing the state of her fingers, doctors swabbed her sores and sent samples from her blisters for testing to a lab.
Results showed that she had developed an herpetic whitlow infection - a finger infection caused by the herpes simplex virus - a common virus that affects about three out of every 100,000 people in the US annually.
There are multiple strains, including HSV-1, which causes oral herpes and cold cores , and HSV-2, which causes genital herpes. It is unclear which strain the woman was diagnosed with.
Typically contracted through infected saliva and genital fluids, the herpetic whitlow infection can also be transmitted through contaminated objects such as shared nail tools or medical equipment.
There is no cure flare ups resulting in open sores and blisters may occur. Treatment plans are usually focused on dealing with symptoms and preventing the spread of the infection.
According to The Oregonian/ Oregon Live, the plaintiff claims in her lawsuit that the nail technician did not wear gloves during the service and stored her manicure tools in an Altoids mints tin.
She also states that did not suffer from the condition in any capacity before receiving the manicure at the salon.
A herpetic whitlow infection is typically caused by the herpes simplex virus 1 (HSV-1) which also causes cold sores or herpes simplex virus 2 (HSV-2), which can cause genital herpes.
The virus can be transmitted through contact with an active herpes lesion, like a cold sore or through contact with infected saliva or genital secretions.
The contagious infection can cause painful blisters, swelling, and redness, often on the fingertip or around the nail bed. Additionally, it can cause a fever and swollen lymph nodes.
The early stages of the infection include pain and a tingling sensation on your finger.
Within days, blisters form near your fingernail, which makes skin to be tender and sensitive.
As the infection progresses, a crust will form as it continues drying and healing. Most cases of herpetic whitlow affect one finger but it can spread to other fingers too depending on the severity of the infection.
A doctor can usually diagnose herpetic whitlow based on the appearance of the lesions and the patient's symptoms.
To confirm the diagnosis, experts may also test a sample of parts of the skin that have been affected.
A herpetic whitlow infection usually resolves on its own but may require an antiviral prescription to help the process.
Medications such as acyclovir, valacyclovir and famciclovir can help shorten the duration and severity of the infection, especially when started early.
Compresses and bandages on the fingers can also help prevent a secondary infection from the virus.
But while a typical herpetic whitlow infection lasts about two weeks, the 23-year-old claims hers has lasted years in continuation as the virus has flared up multiple times.
Due to the infection's contagious nature, as well as the pain her in hands, the woman said she has been forced to repeatedly bandage her fingers to prevent the virus from spreading to others while she is out in public.
She told The Oregonian/Oregon Live: 'The flare-ups can be super, super painful. It's always on my mind.'
'People have asked "What happened to your finger?" I don't want to tell them what it really is because it's really embarrassing.'
According to the lawsuit, she was seeking $1.75 million from the salon claiming negligence and unlawful trade practices.
However, according to The Oregonian/Oregon Live, the patient and salon have now reached a confidential settlement with the business

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
2 hours ago
- Daily Mail
Menopause made my hair fall out. Then I discovered a new hair-loss solution. This is the secret ALL midlife women need to know
For me, midlife has brought various indignities, as well as many joys. But standing over a sink to count the number of hairs that had come out in my brush one morning has to be among the more distressing aspects. For the record, it was 201. And why was I counting them? Because I'd searched 'how to tell if your hair is falling out' online – and according to Dr Google, anything over 100 strands was a cause for concern.


The Independent
3 hours ago
- The Independent
WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs
WeightWatchers was slower to adapt to the emergence of anti-obesity jabs than rivals, its boss has admitted, as the 62-year-old brand strives to catch up with rapidly evolving attitudes towards weight loss. Tara Comonte, chief executive of the US-based business, said it had a lot of work to do after going through a 'reset'. WeightWatchers recently announced it had emerged from bankruptcy after writing off a portion of the 1.15 billion US dollar (£860 million) debt on its balance sheet. It came as the business was competing with the emergence of GLP-1s – the scientific term for weight loss jabs, which work by reducing food cravings – and a new wave of apps and advice spreading on social media. Ms Comonte told the PA news agency that it 'wasn't as quick to medical weight loss solutions' as some other firms in the US, notably so-called 'telehealth' businesses that offer healthcare remotely. WeightWatchers, which runs some 20,000 workshops each month globally, is now 'at the beginning of the journey' towards forging a new place in the industry and meeting demand from current and future members, Ms Comonte said. 'This whole industry is going through somewhat of a reset and we have exciting work to do,' she told the PA news agency. 'This is a moment where, possibly more than ever before, people are talking about weight, and weight health… where people are seeking more education than ever before, and there are more voices than ever before.' Ms Comonte said the brand was known for 'trust and science' and it was important to harness that 'as there are more and more voices in the ecosystem'. WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app. It forms part of its efforts to muscle into the market by offering behavioural strategies and community-based support to people using or coming off the medication. 'There's no 'us and them' anymore,' Ms Comonte told PA, hitting back at weight loss jabs often being pitted as rivals to its model. Dr Kim Boyde, WeightWatchers' newly appointed chief medical officer, said not all its members will want or need weight loss medication – but stressed that it was 'imperative' the programme offers it to those that might benefit. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.


Reuters
4 hours ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.